Journal of Clinical Investigation - Cardiology
SEPTEMBER 3, 2024
Consequently, changes in salivary function can profoundly impair quality of life for cancer patients. We discuss approaches to quantify xerostomia in the clinic, including the advantages and limitations of validated quality-of-life instruments and approaches to directly measuring salivary function.
HeartRhythm
SEPTEMBER 4, 2024
highlight the misperception that pharmacologic heart rate lowering is beneficial, which has resulted in an overprescription of beta-blockers in HFpEF and AF. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
DAIC
JULY 25, 2024
BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.
Frontiers in Cardiovascular Medicine
JUNE 9, 2024
We propose that enhancing lymphatic function pharmacologically may be a novel and effective way to improve quality of life in patients with CKM syndrome by engaging multiple pathologies at once throughout the body.
Heart BMJ
FEBRUARY 12, 2024
Introduction Management of heart failure (HF) requires multidisciplinary, pharmacological and non-pharmacological strategies, one component of which is exercise training.
Stroke Journal
AUGUST 19, 2024
Care should be comprehensive and interdisciplinary.
DAIC
MAY 14, 2024
While invasive interventions can restore selected patients’ quality of life, pharmacologic therapies that are safe, well-tolerated and that reliably improve how patients feel and function remain an unmet need for patients with obstructive HCM.
Expert insights. Personalized for you.
120 
Let's personalize your content